• Reference Citation Analysis
  • v
  • v
  • Find an Article
Find an Article PDF (5077518)   Today's Articles (215)
For: Pignatti F, Ashby D, Brass E, Eichler H, Frey P, Hillege H, Hori A, Levitan B, Liberti L, Löfstedt R, Mcauslane N, Micaleff A, Noel R, Postmus D, Renn O, Sabourin B, Salmonson T, Walker S. Structured Frameworks to Increase the Transparency of the Assessment of Benefits and Risks of Medicines: Current Status and Possible Future Directions. Clin Pharmacol Ther 2015;98:522-33. [DOI: 10.1002/cpt.203] [Citation(s) in RCA: 31] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/22/2015] [Accepted: 08/01/2015] [Indexed: 11/07/2022]
Number Cited by Other Article(s)
1
Pignatti F, Josephson F, Demolis P, Tenhunen O, Péan E, Postmus D. Expedited Approval in Oncology: A Study of European Regulators' Perspectives and Trade-Offs. Clin Pharmacol Ther 2025. [PMID: 40356477 DOI: 10.1002/cpt.3708] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/18/2025] [Accepted: 04/22/2025] [Indexed: 05/15/2025]
2
Kochhar S, Izurieta HS, Chandler RE, Hacker A, Chen RT, Levitan B. Benefit-risk assessment of vaccines. Vaccine 2024;42:969-971. [PMID: 37563049 DOI: 10.1016/j.vaccine.2023.07.041] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/07/2023] [Accepted: 07/20/2023] [Indexed: 08/12/2023]
3
Levitan B, Hadler SC, Hurst W, Izurieta HS, Smith ER, Baker NL, Bauchau V, Chandler R, Chen RT, Craig D, King J, Pitisuttithum P, Strauss W, Tomczyk S, Zafack J, Kochhar S. The Brighton collaboration standardized module for vaccine benefit-risk assessment. Vaccine 2024;42:972-986. [PMID: 38135642 DOI: 10.1016/j.vaccine.2023.09.039] [Citation(s) in RCA: 4] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/24/2023] [Accepted: 09/19/2023] [Indexed: 12/24/2023]
4
De Oliveira Ascef B, Gabriel FC, Suzumura EA, Maia FHDA, Bortoluzzi AFR, Farias NS, Jahn B, Siebert U, De Soarez PC. Methodological guidelines and publications of benefit-risk assessment for health technology assessment: a scoping review protocol. BMJ Open 2023;13:e075333. [PMID: 38072481 PMCID: PMC10729267 DOI: 10.1136/bmjopen-2023-075333] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/04/2023] [Accepted: 10/31/2023] [Indexed: 12/18/2023]  Open
5
Pinto CA, Balantac Z, Mt-Isa S, Liu X, Bracco OL, Clarke H, Tervonen T. Regulatory benefit-risk assessment of oncology drugs: A systematic review of FDA and EMA approvals. Drug Discov Today 2023;28:103719. [PMID: 37467877 DOI: 10.1016/j.drudis.2023.103719] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/25/2023] [Revised: 06/30/2023] [Accepted: 07/13/2023] [Indexed: 07/21/2023]
6
Totton N, Julious SA, Coates E, Hughes DA, Cook JA, Biggs K, Hewitt C, Day S, Cook A. Appropriate design and reporting of superiority, equivalence and non-inferiority clinical trials incorporating a benefit-risk assessment: the BRAINS study including expert workshop. Health Technol Assess 2023;27:1-58. [PMID: 37982521 PMCID: PMC11017151 DOI: 10.3310/bhqz7691] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2023]  Open
7
Sullivan T, Zorenyi G, Feron J, Smith M, Nord M. A Structured Benefit-Risk Assessment Operating Model for Investigational Medicinal Products in the Pharmaceutical Industry. Ther Innov Regul Sci 2023;57:849-864. [PMID: 37005972 PMCID: PMC10276786 DOI: 10.1007/s43441-023-00508-2] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/20/2022] [Accepted: 02/24/2023] [Indexed: 04/04/2023]
8
Tervonen T, Veldwijk J, Payne K, Ng X, Levitan B, Lackey LG, Marsh K, Thokala P, Pignatti F, Donnelly A, Ho M. Quantitative Benefit-Risk Assessment in Medical Product Decision Making: A Good Practices Report of an ISPOR Task Force. VALUE IN HEALTH : THE JOURNAL OF THE INTERNATIONAL SOCIETY FOR PHARMACOECONOMICS AND OUTCOMES RESEARCH 2023;26:449-460. [PMID: 37005055 DOI: 10.1016/j.jval.2022.12.006] [Citation(s) in RCA: 15] [Impact Index Per Article: 7.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 11/01/2022] [Accepted: 12/06/2022] [Indexed: 05/06/2023]
9
Waschbusch M, Rodriguez L, Brueckner A, Lee KJ, Li X, Mokliatchouk O, Tremmel L, Yuan SS. Global Landscape of Benefit-Risk Considerations for Medicinal Products: Current State and Future Directions. Pharmaceut Med 2022;36:201-213. [PMID: 35780471 DOI: 10.1007/s40290-022-00435-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 06/02/2022] [Indexed: 11/24/2022]
10
The value of anticancer drugs - a regulatory view. Nat Rev Clin Oncol 2022;19:207-215. [PMID: 34873312 DOI: 10.1038/s41571-021-00584-z] [Citation(s) in RCA: 18] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 11/09/2021] [Indexed: 12/18/2022]
11
Bloem LT, Vreman RA, Peeters NWL, Hoekman J, van der Elst ME, Leufkens HGM, Klungel OH, Goettsch WG, Mantel-Teeuwisse AK. Associations between uncertainties identified by the European Medicines Agency and national decision making on reimbursement by HTA agencies. Clin Transl Sci 2021;14:1566-1577. [PMID: 33786991 PMCID: PMC8301545 DOI: 10.1111/cts.13027] [Citation(s) in RCA: 16] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/23/2020] [Revised: 03/02/2021] [Accepted: 03/09/2021] [Indexed: 11/30/2022]  Open
12
Verhagen H, Alonso-Andicoberry C, Assunção R, Cavaliere F, Eneroth H, Hoekstra J, Koulouris S, Kouroumalis A, Lorenzetti S, Mantovani A, Menozzi D, Nauta M, Poulsen M, Rubert J, Siani A, Sirot V, Spaggiari G, Thomsen ST, Trevisan M, Cozzini P. Risk-benefit in food safety and nutrition - Outcome of the 2019 Parma Summer School. Food Res Int 2021;141:110073. [PMID: 33641961 DOI: 10.1016/j.foodres.2020.110073] [Citation(s) in RCA: 12] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/20/2020] [Revised: 12/21/2020] [Accepted: 12/22/2020] [Indexed: 12/13/2022]
13
Janssen MP, Nuebling CM, Lery FX, Maryuningsih YS, Epstein JS. A WHO tool for risk-based decision making on blood safety interventions. Transfusion 2020;61:503-515. [PMID: 33368381 PMCID: PMC7898802 DOI: 10.1111/trf.16231] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/26/2020] [Revised: 10/22/2020] [Accepted: 11/25/2020] [Indexed: 11/28/2022]
14
Radawski CA, Hammad TA, Colilla S, Coplan P, Hornbuckle K, Freeman E, Smith MY, Sobel RE, Bahri P, Arias AE, Bennett D. The utility of real-world evidence for benefit-risk assessment, communication, and evaluation of pharmaceuticals: Case studies. Pharmacoepidemiol Drug Saf 2020;29:1532-1539. [PMID: 33146901 DOI: 10.1002/pds.5167] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/27/2019] [Revised: 09/28/2020] [Accepted: 10/31/2020] [Indexed: 12/28/2022]
15
Smith MY, van Til J, DiSantostefano RL, Hauber AB, Marsh K. Quantitative Benefit-Risk Assessment: State of the Practice Within Industry. Ther Innov Regul Sci 2020;55:415-425. [PMID: 33111177 PMCID: PMC7864811 DOI: 10.1007/s43441-020-00230-3] [Citation(s) in RCA: 17] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/27/2020] [Accepted: 10/09/2020] [Indexed: 10/26/2022]
16
Bhasale AL, Sarpatwari A, De Bruin ML, Lexchin J, Lopert R, Bahri P, Mintzes BJ. Postmarket Safety Communication for Protection of Public Health: A Comparison of Regulatory Policy in Australia, Canada, the European Union, and the United States. Clin Pharmacol Ther 2020;109:1424-1442. [PMID: 32767557 DOI: 10.1002/cpt.2010] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/16/2020] [Accepted: 07/25/2020] [Indexed: 12/29/2022]
17
Katz EG, Hough D, Doherty T, Lane R, Singh J, Levitan B. Benefit-Risk Assessment of Esketamine Nasal Spray vs. Placebo in Treatment-Resistant Depression. Clin Pharmacol Ther 2020;109:536-546. [PMID: 32860422 PMCID: PMC7894501 DOI: 10.1002/cpt.2024] [Citation(s) in RCA: 25] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/21/2020] [Accepted: 07/26/2020] [Indexed: 12/28/2022]
18
Angelis A, Thursz M, Ratziu V, O’Brien A, Serfaty L, Canbay A, Schiefke I, Costa JBE, Lecomte P, Kanavos P. Early Health Technology Assessment during Nonalcoholic Steatohepatitis Drug Development: A Two-Round, Cross-Country, Multicriteria Decision Analysis. Med Decis Making 2020;40:830-845. [PMID: 32845234 PMCID: PMC7457462 DOI: 10.1177/0272989x20940672] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/18/2019] [Accepted: 05/13/2020] [Indexed: 12/28/2022]
19
Keyter A, Salek S, Banoo S, Walker S. Can Standardisation of the Public Assessment Report Improve Benefit-Risk Communication? Front Pharmacol 2020;11:855. [PMID: 32625087 PMCID: PMC7313675 DOI: 10.3389/fphar.2020.00855] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/31/2020] [Accepted: 05/22/2020] [Indexed: 11/13/2022]  Open
20
Health Technology Agency insights: informing modification of a qualitative benefit risk framework for Health Technology Reassessment of prescription medications. Int J Technol Assess Health Care 2019;35:384-392. [PMID: 31524113 DOI: 10.1017/s026646231900062x] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
21
Tervonen T, Angelis A, Hockley K, Pignatti F, Phillips LD. Quantifying Preferences in Drug Benefit-Risk Decisions. Clin Pharmacol Ther 2019;106:955-959. [PMID: 30929257 DOI: 10.1002/cpt.1447] [Citation(s) in RCA: 19] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/21/2018] [Accepted: 03/21/2019] [Indexed: 01/13/2023]
22
Pignatti F, Péan E. Regulatory and Evidence Requirements and the Changing Landscape in Regulation for Marketing Authorisation. Recent Results Cancer Res 2019;213:169-187. [PMID: 30543013 DOI: 10.1007/978-3-030-01207-6_11] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/09/2023]
23
A decade of marketing approval of gene and cell-based therapies in the United States, European Union and Japan: An evaluation of regulatory decision-making. Cytotherapy 2018;20:769-778. [PMID: 29730080 DOI: 10.1016/j.jcyt.2018.03.038] [Citation(s) in RCA: 20] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/07/2018] [Revised: 03/29/2018] [Accepted: 03/29/2018] [Indexed: 02/06/2023]
24
McAuslane N, Leong J, Liberti L, Walker S. The Benefit-Risk Assessment of Medicines: Experience of a Consortium of Medium-Sized Regulatory Authorities. Ther Innov Regul Sci 2017;51:635-644. [DOI: 10.1177/2168479017696260] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
25
P Tafti A, Badger J, LaRose E, Shirzadi E, Mahnke A, Mayer J, Ye Z, Page D, Peissig P. Adverse Drug Event Discovery Using Biomedical Literature: A Big Data Neural Network Adventure. JMIR Med Inform 2017;5:e51. [PMID: 29222076 PMCID: PMC5741828 DOI: 10.2196/medinform.9170] [Citation(s) in RCA: 30] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/13/2017] [Revised: 11/07/2017] [Accepted: 11/08/2017] [Indexed: 11/16/2022]  Open
26
Bujar M, McAuslane N, Walker SR, Salek S. Evaluating Quality of Decision-Making Processes in Medicines' Development, Regulatory Review, and Health Technology Assessment: A Systematic Review of the Literature. Front Pharmacol 2017;8:189. [PMID: 28443022 PMCID: PMC5385334 DOI: 10.3389/fphar.2017.00189] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/04/2017] [Accepted: 03/23/2017] [Indexed: 12/02/2022]  Open
27
Liberti L, Breckenridge A, Hoekman J, McAuslane N, Stolk P, Leufkens H. Factors related to drug approvals: predictors of outcome? Drug Discov Today 2017;22:937-946. [PMID: 28288783 DOI: 10.1016/j.drudis.2017.03.003] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/05/2016] [Revised: 02/12/2017] [Accepted: 03/03/2017] [Indexed: 11/15/2022]
28
Bujar M, Donelan R, McAuslane N, Walker S, Salek S. Assessing the Quality of Decision Making in the Development and Regulatory Review of Medicines: Identifying Biases and Best Practices. Ther Innov Regul Sci 2017;51:250-256. [PMID: 30231720 DOI: 10.1177/2168479016662681] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
29
Kurz X. Advancing regulatory science, advancing regulatory practice. Pharmacoepidemiol Drug Saf 2017;26:722-726. [PMID: 28220974 PMCID: PMC5484349 DOI: 10.1002/pds.4181] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/14/2016] [Revised: 12/29/2016] [Accepted: 01/19/2017] [Indexed: 11/21/2022]
30
Hoshikawa K, Ono S. Discrepancies between multicriteria decision analysis-based ranking and intuitive ranking for pharmaceutical benefit-risk profiles in a hypothetical setting. J Clin Pharm Ther 2016;42:80-86. [PMID: 27914099 DOI: 10.1111/jcpt.12486] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/07/2016] [Accepted: 11/04/2016] [Indexed: 11/28/2022]
31
Pharmaceutical Benefit–Risk Communication Tools: A Review of the Literature. Drug Saf 2016;40:15-36. [DOI: 10.1007/s40264-016-0466-1] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
32
DiSantostefano RL, Berlin JA, Chuang-Stein C, Quartey G, Eichenbaum G, Levitan B. Selecting and Integrating Data Sources in Benefit–Risk Assessment: Considerations and Future Directions. Stat Biopharm Res 2016. [DOI: 10.1080/19466315.2016.1225596] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
33
Bujar M, McAuslane N, Salek S, Walker S. Quality of Regulatory Decision-Making Practices: Issues Facing Companies and Agencies. Ther Innov Regul Sci 2016;50:487-495. [PMID: 30227024 DOI: 10.1177/2168479016628573] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
34
Pignatti F, Martinalbo J, Jonsson B, Foggi P. Reply to the letter to the editor ‘Number-Needed-To-Treat for pricing costly anti-cancer drugs. The example of Regorafenib in metastatic colorectal cancer’ by Graziano et al. Ann Oncol 2016;27:958. [DOI: 10.1093/annonc/mdw049] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]  Open
35
Honig PK. Pharmacotherapy for Neurodegenerative Diseases: Are We Approaching the Tipping Point? Clin Pharmacol Ther 2015;98:452-5. [DOI: 10.1002/cpt.209] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/06/2015] [Accepted: 08/06/2015] [Indexed: 01/09/2023]
PrevPage 1 of 1 1Next
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA